Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: Lack of association with clinical outcome

British Journal of Cancer

Volumn 78, Issue 12, 1998, Pages 1645-1652

  Ferrandina, G ^a   Scambia, G ^a   Fagotti, A ^a   D'Agostino, G ^a   Benedetti Panici, P ^a   Carbone, A ^a   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cathepsin D; Ovarian cancer prognosis

Indexed keywords

CATHEPSIN D; ESTROGEN RECEPTOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0031769373     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.737     Document Type: Article

References (33)

1. Altman DG (1992) Categorizing continuous variables. Br J Cancer 64: 975
2. Athanassiadou P, Sakellariou V, Michalas S, Petrkakou E, Athanassiades P and Aravantinos D (1997) Immunocytochemical localization of cathepsin D and Ca125 in ovarian cancer. Int J Gynecol Obst 56: 31-37
3. Bradford AA (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Ann Biochem 72: 248-255
4. Chalbos D, Philips A, Galtier F and Rochefort H (1993) Synthetic antiestrogens modulate induction of pS2 and cathepsin D mRNA by growth factors and cAMP in MCF-7 cells. Endocrinology 33: 571-576
5. Eng Tan P, Cenz CC, Dollbaun C, Moore DH, Edgerton SM, Zava DT and Thort AD (1994) Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol 5: 329-336
6. EORTC Breast Cancer Cooperative Group (1980) Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer 16: 1513-1515
7. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S and Messori A (1997) Relationship between Cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta analysis. Br J Cancer 76: 661-666
8. Galtier-Dereure F, Capony F, Maudelonde T and Rochefort H (1992) Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75: 1497-1502
9. Garcia D, Derocq D, Pujol P and Rochefort H (1990) Overexpression of transfected Cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 5: 1809-1814
10. Gion M, Mione R, Dittadi R, Romanelli M, Pappagallo L, Capitanio G, Friede U, Barbazza R, Visiona A and Dante S (1995) Relationship between cathepsin D and other pathological and biological parameters in 1752 patients with primary breast cancer. Eur J Cancer 31: 671-677
11. Henzen-Logmans S, Fieret EJH, Berns EMJJ, Van Der Burg MEL, Klijn JGM and Foekens JA (1994) Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumours: correlation with steroid receptors, epidermal-growth-factor receptor and Cathepsin D. Int J Cancer 57: 468-472
12. Hsu SM, Raine L and Fanger H (1981) Use of avidine-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580
13. Imort M, Zuhldorf M, Feige U, Hasilik A and Von Figura K (1983) Biosynthesis and transport of lysosomal enzymes in human monocytes and macrophages. Biochem J 214: 671-678
14. International Federation of Gynecology and Obstetrics (1987) Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264
15. Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Knabbaz N and Kallioniemi OP (1993) Cathepsin D expression detected by immunohistochemistry has independent value in axillary node-negative breast cancer. J Clin Oncol 11: 36-43
16. Johnson MD, Westley BR and May FEB (1989) Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 59: 727-738
17. Kozyreva EA, Zhordanina KI, Basalyk LS and Vasil'ev AV (1994) Prognostic significance of determining cathepsin B activity in malignant ovarian tumors. Vopr Med Khim 40: 25-27
18. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Janicke F and Graeff H (1994) Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55: 401-409
19. Liotta LA and Stracke ML (1995) Molecular mechanisms of tumor cell metastasis. In The Molecular Basis of Cancer, Mendelsohn J, Howley PM, Israel MA and Liotta LA. (eds), pp. 233-247. WB Saunders: Philadelphia
20. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising its consideration. Cancer Chemother Rep 50: 163-170
21. Maudelonde T, Escot C, Pujol P, Rouanet P, Defrenne A, Brouillet JP and Rochefort H (1994) In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer. Eur J Cancer 14: 2049-2053
22. Rochefort H, Capony K and Garcia M (1987) Estrogen induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J Cell Biochem 35: 17-29
23. Roger P, Montcourrier P, Maudelonde T, Brouillet JP, Pages A, Laffargue F and Rochefort H (1994) Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol 25: 863-871
24. Scambia G, Benedetti-Panici P, Ferrandina G, Battaglia F, Baiocchi G and Mancuso S (1991) Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone, and epidermal growth factor. Br J Cancer 64: 182-184
25. Scambia G, Benedetti-Panici P, Ferrandina G, Salerno G, D'Agostino G, Distefano M, De Vincenzo R, Ercoli A and Mancuso S (1994) Clinical significance of Cathepsin D in primary ovarian cancer. Eur J Cancer 30: 935-940
26. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A and Mancuso S (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72: 361-366
27. Serov SF, Scully RE and Sobin LM (1973) Histological typing of ovarian tumours. In International Histological Classification of Tumors, Vol. 9. p. 56. World Health Organization: Geneva
28. Simon R and Altman DG (1994) Statistical aspects of prognostic factor studies in oncology. Br J Cancer 69: 979-985
29. Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rouess J, Maudelonde T, Brunet M, Andrieu C, Desplaces A and Rochefort H (1989) Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 2: 1115-1118
30. Van der Stappen JWJ, Williams AC, Rose A, Maciewicz and Paraskeva C (1996) Activation of Cathepsin B, secreted by cancer cell line requires low pH and is mediated by Cathepsin D. Int J Cancer 67: 547-554
31. Vignon F, Capony F, Chambon M, Freiss G, Garcia M and Rochefort H (1986) Autocrine growth stimulation of the MCF-7 breast cancer cells by the estrogen regulated 52k protein. Endocrinology 118: 1537-1540
32. Westley BR and Rochefort H (1979) Estradiol-induced proteins in MCF-7 human breast cancer cell line. Biochem Biophys Res Commun 90: 410-416
33. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO: Geneva pp. 16-21